Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection

Cancer Science

Volumn 105, Issue 11, 2014, Pages 1427-1434

  Fu, Qiang ^a   Liu, Zheng ^a   Pan, Deng ^a   Zhang, Weijuan ^a   Xu, Le ^a   Zhu, Yu ^b   Liu, Haiou ^a   Xu, Jiejie ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer specific survival; Clear cell renal cell carcinoma; MicroRNA 125b; Prognostic biomarker; Recurrence free survival

Indexed keywords

MICRORNA; MIRN125 MICRORNA, HUMAN;

ADULT; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, RENAL CELL; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IN SITU HYBRIDIZATION; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 84911379862     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12507     Document Type: Article

References (45)

1. Nelson EC, Evans CP, Lara PN Jr. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 2007; 33: 299-313.
2. Wach S, Nolte E, Theil A et al. MicroRNA profiles classify papillary renal cell carcinoma subtypes. Br J Cancer 2013; 109: 714-22.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
4. Ljungberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur Urol 2007; 51: 1502-10.
5. Delahunt B, Cheville JC, Martignoni G et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013; 37: 1490-504.
6. Wu X, Weng L, Li X et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS ONE 2012; 7: e35661.
7. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-9.
8. Catto JW, Alcaraz A, Bjartell AS et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011; 59: 671-81.
9. White NM, Bao TT, Grigull J et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011; 186: 1077-83.
10. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
11. Heinzelmann J, Unrein A, Wickmann U et al. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases. Ann Surg Oncol 2013; 21: 1046-54.
12. Vergho D, Kneitz S, Rosenwald A et al. Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer 2014; 14: 25.
13. White NM, Yousef GM. MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. BMC Med 2010; 8: 65.
14. Saini S, Yamamura S, Majid S et al. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 2011; 71: 6208-19.
15. Silva-Santos RM, Costa-Pinheiro P, Luis A et al. MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer 2013; 109: 2646-53.
16. Heinzelmann J, Henning B, Sanjmyatav J et al. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 2011; 29: 367-73.
17. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4.
18. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 4559-66.
19. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395-400.
20. Kim SP, Alt AL, Weight CJ et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol 2011; 185: 2035-9.
21. Ficarra V, Galfano A, Mancini M, Martignoni G, Artibani W. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol 2007; 8: 554-8.
22. Novara G, Ficarra V, Antonelli A et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 2010; 58: 588-95.
23. ggener S. TNM staging for renal cell carcinoma: time for a new method. Eur Urol 2010; 58: 517-9; discussion 9-21.
24. Patard JJ, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22: 3316-22.
25. Thompson RH, Leibovich BC, Lohse CM et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 2007; 177: 477-80.
26. Iimura Y, Saito K, Fujii Y et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009; 181: 1004-12; discussion 12.
27. McCormick RI, Blick C, Ragoussis J et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer 2013; 108: 1133-42.
28. Huang L, Luo J, Cai Q et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011; 128: 1758-69.
29. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011; 71: 538-49.
30. Gong J, Zhang JP, Li B et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013; 32: 3071-9.
31. Guan Y, Yao H, Zheng Z, Qiu G, Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer 2011; 128: 2274-83.
32. Hofmann MH, Heinrich J, Radziwill G, Moelling K. A short hairpin DNA analogous to miR-125b inhibits C-Raf expression, proliferation, and survival of breast cancer cells. Mol Cancer Res 2009; 7: 1635-44.
33. Bousquet M, Quelen C, Rosati R et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008; 205: 2499-506.
34. Xia HF, He TZ, Liu CM et al. MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem 2009; 23: 347-58.
35. Nishida N, Yokobori T, Mimori K et al. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol 2011; 38: 1437-43.
36. Medrano S, Monteagudo MC, Sequeira-Lopez ML, Pentz ES, Gomez RA. Two microRNAs, miR-330 and miR-125b-5p, mark the juxtaglomerular cell and balance its smooth muscle phenotype. Am J Physiol Renal Physiol 2012; 302: F29-37.
37. Ferracin M, Bassi C, Pedriali M et al. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol Cancer 2013; 12: 130.
38. Wan Y, Fei XF, Wang ZM et al. Expression of miR-125b in the new, highly invasive glioma stem cell and progenitor cell line SU3. Chin J Cancer 2012; 31: 207-14.
39. von Brandenstein M, Pandarakalam JJ, Kroon L et al. MicroRNA 15a, inversely correlated to PKCalpha, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol 2012; 180: 1787-97.
40. Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlback B. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer 2014; 50: 1758-65.
41. Haemmig S, Baumgartner U, Gluck A et al. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis 2014; 5: e1279.
42. Gurova KV, Hill JE, Guo C et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A 2005; 102: 17448-53.
43. Parlato S, Bruni R, Fragapane P et al. IFN-alpha regulates Blimp-1 expression via miR-23a and miR-125b in both monocytes-derived DC and pDC. PLoS ONE 2013; 8: e72833.
44. Wang YD, Cai N, Wu XL, Cao HZ, Xie LL, Zheng PS. OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway. Cell Death Dis 2013; 4: e760.
45. Gazda LS, Martis PC, Laramore MA et al. Treatment of agarose-agarose RENCA macrobeads with docetaxel selects for OCT4(+) cells with tumor-initiating capability. Cancer Biol Ther 2013; 14: 1147-57.